Basic skin care (basic therapy) is a mainstay in the treatment of atopic dermatitis, irrespective of disease severity and current disease activity. Consistent application of basic skin care plays a key role in restoring skin barrier function and reducing xerosis as well as pruritus. Moreover, it has been shown that concurrent basic therapy has steroid-sparing effects in acute disease flares. In long-term atopic dermatitis management, the use of basic skin care is associated with prolonged recurrence-free intervals. Recent studies have also demonstrated that early initiation of basic skin therapy has protective effects in infants at risk of developing atopic dermatitis. The present review addresses these topics with a focus on established treatments and new developments.
Introduction
A chronic infl ammatory skin disease, atopic dermatitis (AD) is one of the most common dermatoses, with a prevalence of about 3 % in adults and 10-15 % in children [ 1, 2 ] , Genetic predisposition, exogenous triggers (including microorganisms, allergens, irritants, climate) and endogenous factors (mental distress, hormones, and others) are involved in the initial onset of the disease as well as fl are-ups and exacerbations [ 2 ] . The defective barrier function of the skin is a key factor in atopic dermatitis, which is further augmented by the cutaneous infl ammatory response, ultimately resulting in self-sustaining dermatitis [ 3, 4 ] , Restoring the impaired barrier function plays a pivotal role in the therapeutic management of atopic dermatitis. National and international guidelines therefore include basic skin care in the management of patients with atopic dermatitis, irrespective of disease stage or severity [ 5, 6 ] ,
Barrier function of the skin
The barrier function of the skin is primarily based on its cellular components, intercellular lipid lamellae and epidermal (structural) proteins [ 7 ] . The structural framework is formed by the stratum corneum and the nucleated epidermis, whose cells are connected by tight junctions and desmosomes.
Other essential components are intercellular lipid lamellae consisting of cholesterol, free fatty acids and ceramides (sphingolipids). Important structural proteins involved in the barrier function include basal and suprabasal keratins. The cornifi ed envelope proteins of the upper epidermis represent another component of the skin barrier. They include loricrin, involucrin and small proline-rich proteins, which bind lipids covalently, and fi laggrin, which is involved in the aggregation of keratins [ 7 ] . This architecture (presented herein in a very simplifi ed manner) can be disrupted at various different levels in patients with AD. One such level is altered fi laggrin expression, either due to genetic mutations, exposure to exogenous factors, or cytokines released during the infl ammatory response [ 8 ] . Other factors that have been reported in patients with AD include the altered composition of epidermal lipids, with a reduction of ceramides and/or a modifi ed composition thereof [ 9 ] . As a consequence of the impaired barrier function, various microbial, irritant, allergenic or nonspecifi c factors that trigger AD can initiate or augment the cutaneous infl ammatory response.
Basic skin care (basic therapy)
The primary goal of basic skin therapy is restoration and maintenance of the epidermal skin barrier. Selection of the appropriate base depends on the stage of the disease and the current condition of the skin, and may need to be adjusted over the course of treatment [ 10 ] . Ideally, basic skin care is applied to the entire body twice daily, not just to areas that are obviously affected by AD. Given that the alterations in barrier lipids and the epidermal differentiation complex are largely genetically determined, lifelong treatment may be required, possibly with a reduced frequency of application. The activity of sebaceous glands is under hormonal control; xerosis cutis is therefore particularly pronounced in children and elderly individuals. There is little evidence that application of creams is effective in downregulating sebaceous gland activity. Various active substances can be incorporated into the base to optimize treatment. In this context, urea has been used the longest; it is a component of the natural moisturizing factor (NMF) of the epidermis [ 11 ] . Application of a topical agent containing urea 5-10 % leads to hydration of the stratum corneum and a reduction in the SCORAD index [ 12, 13 ] . A urea content of ≥ 10 % also improves the penetration of corticosteroids [ 14 ] . In vitro studies have shown that urea reduces epidermal proliferation and increases the synthesis of barrier lipids and antimicrobial peptides. This involves regulation of the expression of genes that play a role in the differentiation of keratinocytes (TG-1, involucrin, loricrin, fi laggrin) and in the synthesis of antimicrobial peptides (LL-37, β -defensin 2) as well as barrier-relevant lipids [ 15 ] . It is therefore safe to assume that the addition of urea to basic skin care products has positive effects on keratinocyte function and the synthesis of barrier lipids [ 15 ] .
It has also been shown that the use of topical medications that contain urea can signifi cantly prolong recurrence-free intervals in patients with AD [ 16 ] . There is no signifi cant clinical difference between a urea content of 5 % and 10 %. Basic skin care products with a high urea content can be associated with an unpleasant burning or stinging sensation, especially in children. In such cases, glycerin represents an alternative; it has been shown to reduce skin dryness, redness and irritation. Given that glycerin promotes hydration of the stratum corneum, it also decreases transepidermal water loss (Table 1 ) . Glycerin, too, is clinically effective against pruritus [ 17 ] .
Apart from these two "classic" agents, other active substances have been introduced for basic therapy in recent years, which are already commercially available in topical formulations. Ceramides are essential components of lipids in the stratum corneum, and are defi cient in patients with atopic dermatitis [ 18 ] . Based on these fi ndings, topical preparations for basic skin therapy have been developed in order to compensate for this defi ciency; these contain ceramide precursors such as hydroxypalmitoyl sphinganine or synthetic ceramides [ 19 ] . In addition to a hydrating effect, these agents also improve skin barrier function (Table 1 ) [ 20 ] . In a double-blind randomized clinical trial of patients with mild AD, it was shown (split-side comparison) that application of a topical agent containing ceramides resulted in a signifi cantly greater improvement in the SCORAD index than basic skin care with cold cream. The reduction in the SCORAD index was equivalent to that produced by topical treatment with hydrocortisone alone (split-side comparison) [ 21 ] .
The cutaneous infl ammatory response plays a key role in maintaining an impaired barrier function in patients with AD. For the colon, it has been repeatedly shown that the interaction between microorganisms and the immune system can induce tolerogenic or antiinfl ammatory immune responses. This concept has also been successfully applied to treatment of the skin [ 22 ] . In two prospective randomized studies, it was shown that application of a lysate of the gram-negative nonpathogenic bacterium Vitreoscilla (V.) fi liformis (incorporated into a base cream) led to a signifi cant reduction in the SCORAD index in patients with atopic dermatitis [ 23, 24 ] . The underlying mechanisms were analyzed using in vitro and in vivo tests, showing that V. fi liformis induces tolerogenic dendritic cells and regulatory (Tr1) cells, which inhibit the proliferation of T helper cells and thus contribute to a reduction in cutaneous infl ammation [ 25 ] . In the future, topical agents containing microbial components that induce tolerogenic immune responses might be an increasingly used option in basic skin therapy.
A recent development in the fi eld of basic skin care involves the actual pharmaceutical formulation. The use of special physical manufacturing processes (high-pressure homogenization) allows for the incorporation of lamellar structures of hydrogenated phospholipids into topical preparations [ 26 ] . Such creams and lotions are characterized by a lamellar lipid bilayer, similar to that found in the stratum corneum. These products are commercially available under names such as DMS (Derma Membrane Structure) or BioMimetic. Due to [ 12-15, 17, 20, 21 ] .
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Antimicrobial the physical manufacturing process, conventional emulsifi ers (such as polyethylene glycol) are no longer necessary. This is an advantage regarding long-term use as it has been shown that preparations containing classic oil-in-water emulsifi ers can have irritant effects when applied to atopic skin for prolonged periods of time, given that they are able to penetrate into deeper layers of the epidermis. By contrast, hydrogenated phosphatidylcholines remain in the stratum corneum, where they facilitate barrier regeneration [ 27 ] .
Recent fi ndings also indicate that basic skin care has a positive effect on other factors that promote AD. Patients with AD frequently exhibit reduced diversity of the skin microbiome and a preponderance of staphylococci, which are a potential trigger for disease fl ares and exacerbations [ 3, 4, 28 ] . It has been shown that consistent basic skin therapy can reduce the number of staphylococci and increase the diversity of the skin microbiome [ 29 ] .
Basic skin care as a preventive measure
The preventive use of basic skin therapy is a relatively new fi eld. As regards secondary prevention, data from epidemiological studies and animal models suggests that the impaired barrier function (whether due to changes in structural proteins such as fi laggrin, the infl ammatory process, or changes in the microbiome) increases percutaneous sensitization by airborne and food allergens in patients with atopic dermatitis.
Experiments on mice with a frameshift mutation of the FLG gene showed enhanced cutaneous allergen priming [ 30 ] . A study of 359 children under the age of 15 months with atopic dermatitis and known sensitization to milk and/or chicken found an increased risk of sensitization to peanut antigen in dust. There was a correlation with the severity of the skin lesions, which supports the hypothesis of percutaneous sensitization. However, in contrast to other reports, that study found no association with mutations in the FLG gene [ 31 ] . It is conceivable that consistent basic skin therapy (and treatment of dermatitis) might reduce the risk of (further) sensitizations. However, there is as yet no relevant data from clinical studies.
With respect to primary prevention, several studies have been published that show a signifi cant reduction in the risk of developing atopic dermatitis if children at risk (those who have a fi rst-degree relative with AD) receive full-body basic skin therapy early on. For example, a small pilot study (2010) showed a marked reduction in the incidence of AD during the fi rst 18 months of life due to daily treatment with an oil-in-water emulsion starting in the fi rst week of life [ 32 ] . The same group then conducted a randomized trial of 124 children at risk (a fi rst-degree relative with atopic disease). Treatment had to be started within the fi rst three weeks of life; the parents had a choice of three different topical preparations with different pharmaceutical formulations (oil, cream or ointment). At the end of the trial after six months, data from 108 children were included in the analysis. There was a 50 % reduction in the risk of developing AD by the end of the trial (RR 0.50, 95 % CI, 0.28-0.9; p = 0.017) [ 33 ] . These fi ndings were confi rmed by a Japanese group in a very similar randomized trial [ 34 ] . The intensifi ed use of oil baths (3-7 times per week) also resulted in a signifi cant reduction in eczematous lesions in a Norwegian study of infants with xerosis cutis (probable eczema: 4 % in the intervention group versus 19 % in the control group) [ 35 ] .
All studies showed excellent tolerability and good acceptance of the treatment. Further large-scale studies on this issue are currently being conducted and will show whether the effects observed so far are i) merely due to the masking of mild forms of AD by early basic therapy, ii) due to the postponement of disease onset, or iii) whether they are the result of a therapeutic measure that is actually associated with long-lasting effectiveness in terms of primary prevention of atopic disorders. For this particular target group of infants and small children, special attention has to be paid to tolerability and effi cacy when selecting a product for basic skin therapy.
Conclusion and prospects
Basic skin care (basic therapy) is a mainstay in the treatment of atopic dermatitis. Insights from basic research have led to a re-evaluation of established agents and the use of new medications in basic skin therapy. New pharmaceutical procedures have expanded the spectrum of basic therapies available and allow us to better meet individual requirements. Further trials that more accurately characterize the potential of "new" therapies compared to "classic" treatments in acute disease, during symptom-free intervals, or for prevention are desirable in order to promote the role of basic skin care and to be able to more accurately classify relevant products.
